GlaxoSmithKline plc’s Dividend Prospects For 2014 And Beyond

G A Chester analyses the income outlook for GlaxoSmithKline plc (LON:GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many top FTSE 100 companies are currently offering dividends that knock spots off the interest you can get from cash or bonds.

In this festive series of articles, I’m assessing how the companies measure up as income-generators, by looking at dividends past, dividends present and dividends yet to come.

Today, it’s the turn of pharmaceuticals giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Dividends past

The table below shows GSK’s five-year dividend record.

  2008 2009 2010 2011 2012
Dividend per share 57p 61p 65p 70p 74p
Dividend growth 7.5% 7.0% 6.6% 7.7% 5.7%

As you can see, GSK has increased its dividend at a fairly steady rate over the last five years. The average annual increase comes out at 6.9% — well ahead of inflation.

This has been a difficult period for GSK. Earnings have been under pressure from cutbacks in government healthcare budgets, expiring patents on some of GSK’s major products, company restructuring costs and some hefty legal settlements.

Despite these negatives, the total of 327p a share paid in dividends over the last five years has been covered 1.3 times by warts-and-all statutory earnings per share (EPS) of 427p. For the latest year (2012), statutory EPS cover of the 74p dividend was in line with the overall 1.3, while cover was 1.5 based on GSK’s ‘core’ (underlying) EPS of 112.7p.

A solid dividend performance through testing times.

Dividends present

GSK has so far paid three quarterly dividends totaling 55p for the current year. Most analysts are expecting a final dividend of 23p when the company announces its annual results on 5 February — giving a 2013 full-year payout of 78p (up 5.4% on 2012). Core EPS is expected to be modestly ahead of last year, maintaining dividend cover at around the 1.5 level.

At a share price of 1,620p, GSK’s current-year dividend represents a yield of 4.8%.

Dividends yet to come

Analysts are forecasting GSK’s dividend to rise by 5.1% to 82p for 2014, which suggests the following schedule:

  Q1 Q2 Q3 Q4
Provisional announcement date 30 April 23 July 22 October February 2015
Forecast amount 19p 19p 20p 24p

Again, analysts expect core EPS to be modestly ahead of the previous year, maintaining dividend cover at around the 1.5 level.

Looking further ahead, GSK is over the hump of its patent expiries, has a strong pipeline of new products coming to market, and management has identified £1bn of new annual cost savings by 2016.

Shareholders can be optimistic about continued annual dividend increases ahead of inflation.

Is this a top choice for growing wealth now?

Before deciding, we think this pick is another must-see.

Discover ‘One Top Growth Stock from The Motley Fool’ absolutely FREE.

Though past performance does not guarantee future results, over the past 5 years, it’s seen consistent double-digit revenue growth. ‘Return on capital’ - a key measure of business quality - is a colossal 57%. That’s almost 6 times higher than the UK average!

Best of all, it has a cult-like following. Customers who’re raving fans, potentially spending more money, more often - whatever the economy.

In our experience, discoveries like this are extremely rare.

So please, don’t leave without seeing, ‘One Top Growth Stock from The Motley Fool’, which includes both the Risks and opportunities.

Claim your FREE copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> G A Chester does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Is the Rolls-Royce share price still undervalued in 2025?

After massive growth in the Rolls-Royce share price, Charlie Carman considers whether the FTSE 100 aerospace and defence stock is…

Read more »

Investing Articles

How an investor could target a £43k lifelong passive income starting with just £5 a day

Harvey Jones says it's possible to build a high-and-rising passive income by investing small, regular sums in FTSE 100 shares.…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

£10,000 invested in Lloyds shares on 7 April is already worth…

After a dip in early April, Lloyds shares are back to their 30%+ year-to-date gain in 2025. And analysts are…

Read more »

US Stock

What I’d look to buy as the US stock market heads for the worst month since 1932

Jon Smith sifts through the US stock market to try and find some ideas that have fallen in value recently…

Read more »

Growth Shares

Prediction: I think £1,000 invested in this UK stock could double by 2030

Jon Smith runs through a FTSE 250 stock with a market cap just over £1bn that he feels has the…

Read more »

Investing Articles

With £10k in savings, here’s how an investor could target a second income of £500 a month

£10k in savings could be the foundation needed towards a powerful second income. Our writer details some steps necessary to…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing For Beginners

£1k invested in the FTSE 100 on ‘Liberation Day’ is now worth…

Jon Smith talks about the volatility in the FTSE 100 in the weeks since the tariff announcements and flags up…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

Barclays’ share price is down 7% from March, so is now the right time for me to buy?

Barclays’ share price has dipped recently, which could mean a bargain to be had. I took a deep dive into…

Read more »